WO2021251603A1 - 지방세포 분화 억제제 및 이를 포함하는 조성물 - Google Patents
지방세포 분화 억제제 및 이를 포함하는 조성물 Download PDFInfo
- Publication number
- WO2021251603A1 WO2021251603A1 PCT/KR2021/004242 KR2021004242W WO2021251603A1 WO 2021251603 A1 WO2021251603 A1 WO 2021251603A1 KR 2021004242 W KR2021004242 W KR 2021004242W WO 2021251603 A1 WO2021251603 A1 WO 2021251603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adipocyte differentiation
- extract
- weight
- differentiation inhibitor
- parts
- Prior art date
Links
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 98
- 230000004069 differentiation Effects 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000003112 inhibitor Substances 0.000 title claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 92
- 239000002537 cosmetic Substances 0.000 claims abstract description 40
- 244000019459 Cynara cardunculus Species 0.000 claims abstract description 30
- 235000019106 Cynara scolymus Nutrition 0.000 claims abstract description 30
- 235000016520 artichoke thistle Nutrition 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 22
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 235000019693 cherries Nutrition 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- QUAPPCXFYKSDSV-LBPRGKRZSA-N (2s)-5,7-dihydroxy-6-methoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2OC3=CC(O)=C(C(=C3C(=O)C2)O)OC)=CC=CC=C1 QUAPPCXFYKSDSV-LBPRGKRZSA-N 0.000 claims description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000574138 Ozothamnus diosmifolius Species 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- ZFKKRRMUPBBYRS-UHFFFAOYSA-N norwogonin Chemical compound OC=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZFKKRRMUPBBYRS-UHFFFAOYSA-N 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- GPDJGLOROGNHJD-UHFFFAOYSA-N 5,6,7-trihydroxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C=2C(O)=C(O)C(O)=CC=2OC1C1=CC=CC=C1 GPDJGLOROGNHJD-UHFFFAOYSA-N 0.000 claims description 6
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 240000004731 Acer pseudoplatanus Species 0.000 claims description 5
- 235000002754 Acer pseudoplatanus Nutrition 0.000 claims description 5
- 235000006485 Platanus occidentalis Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 3
- KIHKKNWFLFSAHD-YXXBAVPESA-N CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O Chemical compound CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O KIHKKNWFLFSAHD-YXXBAVPESA-N 0.000 claims description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 3
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 claims description 3
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical group O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 claims description 3
- 229940015301 baicalein Drugs 0.000 claims description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003321 baicalin Drugs 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 239000010404 Scutellaria baicalensis extract Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000000605 extraction Methods 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 15
- 230000011759 adipose tissue development Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000004130 lipolysis Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 241001290151 Prunus avium subsp. avium Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 208000035484 Cellulite Diseases 0.000 description 6
- 206010049752 Peau d'orange Diseases 0.000 description 6
- 230000036232 cellulite Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000000229 preadipocyte Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000002366 lipolytic effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- KRZBCHWVBQOTNZ-RDJMKVHDSA-N (3r,5r)-3,5-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KRZBCHWVBQOTNZ-WXAIXHMISA-N 3,5-di-O-caffeoylquinic acid Natural products O[C@@H]1[C@H](C[C@](O)(C[C@@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-WXAIXHMISA-N 0.000 description 4
- FKIYLTVJPDLUDL-ZWUNSDNISA-N Apigenin 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 FKIYLTVJPDLUDL-ZWUNSDNISA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- FKIYLTVJPDLUDL-SLNHTJRHSA-N Isorhoifolin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1 FKIYLTVJPDLUDL-SLNHTJRHSA-N 0.000 description 4
- FKIYLTVJPDLUDL-FLPYCHHVSA-N Isorhoifolin Natural products C[C@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)cc5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H](O)[C@@H]1O FKIYLTVJPDLUDL-FLPYCHHVSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102100031786 Adiponectin Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007443 liposuction Methods 0.000 description 3
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 description 2
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical group O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 description 2
- 229950009125 cynarine Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 2
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100102503 Caenorhabditis elegans ver-3 gene Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 206010040102 Seroma Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930193997 cynaroside Natural products 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Definitions
- the present invention relates to an adipocyte differentiation inhibitor capable of inhibiting the differentiation of adipocytes and reducing the production of fat, and a cosmetic or food composition that can safely and inexpensively obtain the effect of subcutaneous fat decomposition by including the adipocyte differentiation inhibitor.
- Liposuction which can remove local fat such as abdominal fat, has been made in order to relieve the obesity.
- Such liposuction has the advantage of being able to maintain the condition permanently and seeing a visible effect relatively easily and quickly, but it requires general and local anesthesia depending on the site, and has the disadvantage of damaging muscles, blood vessels, and lymphatic vessels during the procedure. , resulting in contour irregularity, seroma, hyperpigmentation, asymmetry, hypertrophic scar, skin necrosis, infection, etc. There is a problem that serious side effects occur.
- non-surgical therapies have emerged to compensate for the serious side effects of liposuction.
- lipolytic injection which is a subcutaneous injection of a substance having a lipolytic action
- dietary therapy drug therapy, and the like.
- non-surgical therapy cannot completely solve obesity, there is no guarantee of safety, and side effects such as yo-yo phenomenon appear.
- An object of the present invention is to provide an adipocyte differentiation inhibitor capable of inhibiting the differentiation of adipocytes and reducing the production of adipocytes.
- Another object of the present invention is to provide a cosmetic composition comprising the adipocyte differentiation inhibitor.
- Another object of the present invention is to provide a food composition comprising the adipocyte differentiation inhibitor.
- the present invention in order to solve the above problems, gold extract; And it provides an adipocyte differentiation inhibitor comprising an artichoke leaf extract.
- the golden extract is baicalein, baicalin, dihydrobaicalein, oroxylin A, dihydrooroxylin A, ogonin and norogo It may include one or more selected from the group consisting of nin (Norwogonin).
- the artichoke leaf extract is cynarine, cinaroside, hydroxycinnamic acid, 3,5-di-O-caffeoylquinic acid (3,5-di-O-caffeoylquinic acid) ) and apigenin-7-rutinoside (apigenin-7-rutinoside) may include one or more selected from the group consisting of.
- the mixing ratio of the golden extract and the artichoke leaf extract may be a weight ratio of 1:1 to 5:1.
- the adipocyte differentiation inhibitor may further include at least one selected from the group consisting of caffeine, peptides and ginkgo leaf extract.
- the peptide may be at least one selected from the group consisting of peptides represented by Valine-Histidine-Valine-Valine (VHVV), Isoleucine-Leucine-Leucine (ILL), and Leucine-Leucine-Leucine (LLL).
- VHVV Valine-Histidine-Valine-Valine
- ILL Isoleucine-Leucine-Leucine
- LLL Leucine-Leucine-Leucine
- the present invention provides a cosmetic composition comprising a spicule.
- the spicule may be coated with a hydrolyzed protein or a hydrophilic material.
- Such a cosmetic composition may further include one or more selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract.
- the present invention provides a food composition comprising the adipocyte differentiation inhibitor.
- the cosmetic composition and/or food composition according to the present invention is safe for the human body because it contains an adipocyte differentiation inhibitor containing a complex extract component derived from a natural product, and can achieve the effect of reducing lipogenesis or decomposing fat at low cost.
- FIG. 2 shows the evaluation results of whether the artichoke leaf extract contained in the adipocyte differentiation inhibitor according to the present invention inhibits adipocyte differentiation and reduces adipogenesis.
- the present invention relates to an adipocyte differentiation inhibitor and a cosmetic composition comprising the same, in which adipocyte differentiation inhibition and adipogenesis reduction (lipolysis) effects can be obtained through a complex extract derived from natural ingredients.
- adipocyte differentiation inhibitor and a cosmetic composition comprising the same, in which adipocyte differentiation inhibition and adipogenesis reduction (lipolysis) effects can be obtained through a complex extract derived from natural ingredients.
- the extract in the present invention may be a concept including an extract obtained through the extraction process of the raw material, a fraction obtained by fractionating the obtained extract, a filtrate obtained by filtering the obtained extract, and a concentrate obtained by concentrating the obtained extract under reduced pressure.
- the method for preparing the extract is hot water extraction method, immersion extraction method, steam distillation method, cold extraction method, reflux cooling extraction method, ultrasonic extraction method, supercritical extraction method, subcritical extraction method, solvent extraction method, elution in consideration of the degree of extraction or preservation of the active ingredient
- a method, a compression method, a high temperature extraction method, or a high pressure extraction method may be applied.
- the adipocyte differentiation inhibitor according to the present invention includes a golden extract and an artichoke leaf extract.
- the golden extract contained in the adipocyte differentiation inhibitor according to the present invention may be obtained by washing and drying gold, and preparing the extract described above. Specifically, it may be obtained through an extraction process using a solvent, followed by filtration and/or drying.
- a solvent used in the extraction process
- water, methanol, ethanol, ethyl acetate, or a mixture thereof may be used. More specifically, the extraction process may consist of extracting washed and dried golden roots with an extraction solvent at 70 to 90° C. for 2 to 6 hours, followed by filtering and dilution.
- the gold (Scutellaria Baicalensis) is a plant with almost no odor and a slightly bitter taste.
- the golden extract obtained using this gold can act to inhibit the accumulation of fat, and the adipocyte differentiation inhibitor according to the present invention contains the golden extract having such an action, thereby providing excellent inhibition of adipocyte differentiation and adipogenesis. reduction effect can be obtained.
- the golden extract contains a compound involved in the inhibition of adipocyte differentiation, and more specifically, baicalein, baicalin, dihydrobaicalein, oroxylin A.
- Dihydrooroxylin A Dihydrooroxylin A
- Ogonin Wigonin
- the golden extract may include one or more compounds selected from the group consisting of Norwogonin (Norwogonin).
- the content of the golden extract may be 5 to 50 parts by weight, specifically 10 to 25 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, considering the inhibition of adipocyte differentiation and interaction with other components.
- the artichoke leaf extract contained in the adipocyte differentiation inhibitor according to the present invention may be obtained by washing and drying artichoke leaves and preparing the extract described above. Specifically, it may be obtained through an extraction process using a solvent, followed by filtration and/or drying.
- a solvent used in the extraction process
- water, methanol, ethanol, ethyl acetate, or a mixture thereof may be used. More specifically, the extraction process may consist of extracting the washed and dried artichoke leaves with an extraction solvent at 20 to 30° C. for 20 to 40 hours, heating and concentration, and then filtering and diluting.
- the artichoke is a plant that grows near the beach and looks similar to a thistle.
- the artichoke leaf extract obtained by using the leaf of the artichoke is capable of lipolytic action, and the adipocyte differentiation inhibitor according to the present invention contains the artichoke leaf extract having this action, thereby providing excellent inhibition of adipocyte differentiation and It can have the effect of reducing fat production.
- the artichoke leaf extract contains compounds involved in lipolysis, and more specifically, Cynarine, Cynaroside, Hydroxycinnamic acid, 3,5-di- O-caffeoylquinic acid (3,5-di-O-caffeoylquinic acid) and apigenin-7-rutinoside (apigenin-7-rutinoside) may be included.
- the content of the artichoke leaf extract is 5 to 50 parts by weight, specifically 10 to 25 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, considering the inhibition of adipocyte differentiation, lipolysis, and interaction with other components. can be negative
- the mixing ratio (a:b) of the golden extract (a) and the artichoke leaf extract (b) included in the adipocyte differentiation inhibitor is 1:1 to 5: It may be a weight ratio of 1, specifically, it may be a weight ratio of 1:1 to 2:1.
- the adipocyte differentiation inhibitor according to the present invention may further include at least one selected from the group consisting of caffeine, peptides and ginkgo leaf extract to increase its efficacy.
- Caffeine further included in the adipocyte differentiation inhibitor according to the present invention, may act to inhibit the differentiation of adipocytes and to inhibit the decomposition of norepinephrine, which promotes fat breakdown.
- the caffeine content may be 0.5 to 5 parts by weight, specifically 1 to 2 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, in consideration of adipocyte differentiation inhibition, lipolysis, and interaction with other components. .
- the peptides included in the adipocyte differentiation inhibitor according to the present invention have a lipolytic action, specifically, Valine-Histidine-Valine-Valine (VHVV), Isoleucine-Leucine-Leucine (ILL) and Leucine-Leucine-Leucine (LLL). ) may be one or more selected from the group consisting of peptides represented by
- the content of the peptide may be 0.5 to 10 parts by weight, specifically 1 to 5 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, in consideration of lipolysis and interaction with other components.
- the ginkgo leaf extract further included in the adipocyte differentiation inhibitor according to the present invention may be obtained by washing and drying ginkgo leaves and preparing the extract described above. Specifically, it may be obtained through an extraction process using a solvent, followed by filtration and/or drying.
- a solvent used in the extraction process
- water, methanol, ethanol, ethyl acetate, or a mixture thereof may be used as the extraction solvent used in the extraction process.
- the Ginkgo biloba leaf extract obtained through this process can act as a lipolytic agent.
- the content of the ginkgo biloba extract may be 0.1 to 10 parts by weight, specifically 1 to 5 parts by weight, based on 100 parts by weight of the adipocyte differentiation inhibitor, in consideration of lipolysis and interaction with other components.
- the above-described adipocyte differentiation inhibitor according to the present invention contains extracts derived from natural products in a complex manner, and includes extracts with good interaction between each component. effect can be shown.
- the adipocyte differentiation inhibitor according to the present invention may further include a commonly known solvent (eg, purified water) for dispersibility and concentration control.
- a commonly known solvent eg, purified water
- the content of the solvent is not particularly limited, and may be the remaining amount excluding the content of each component (active ingredient) described above.
- the present invention provides a cosmetic composition capable of exhibiting effects such as lipolysis, skin roughness improvement, and cellulite improvement by including the above-described adipocyte differentiation inhibitor.
- the cosmetic composition according to the present invention includes an adipocyte differentiation inhibitor and spicule.
- the adipocyte differentiation inhibitor included in the cosmetic composition according to the present invention serves to impart functions such as regulating adipogenesis, lipolysis, and improvement of cellulite to the cosmetic composition.
- the description of the adipocyte differentiation inhibitor is the same as described above, and thus will be omitted.
- the content of the adipocyte differentiation inhibitor may be 0.05 to 5 parts by weight, specifically 0.1 to 2 parts by weight, based on 100 parts by weight of the cosmetic composition, in consideration of the overall efficacy and manufacturing efficiency of the cosmetic composition.
- the spicule included in the cosmetic composition according to the present invention plays a role in deeply penetrating the components contained in the cosmetic composition together with the adipocyte differentiation inhibitor into the skin.
- the spicule has a needle-like shape (eg, needle-shaped, conical, pyramid-shaped), and the spicule may form a hole in the skin to promote physical transdermal absorption of the cosmetic composition.
- the spicule can also perform a function of penetrating into the skin and pushing up the keratin accumulated on the skin to remove it, so that it can also impart a skin regeneration function to the cosmetic composition.
- the spicule may be coated with a hydrolyzed protein or a hydrophilic material in order to increase the binding rate (inclusion rate) with the components contained in the cosmetic composition.
- the hydrolyzed protein is specifically hydrolyzed collagen, hydrolyzed silk, hydrolyzed keratin, hydrolyzed elastin, hydrolyzed soy protein, hydrolyzed wheat protein and hydrolyzed sericin. It may be at least one selected from the group consisting of.
- the hydrophilic material may be at least one selected from the group consisting of glycerol, ethylene glycol, diethylene glycol (DEG) and polyethylene glycol (PEG).
- the content of the spicule may be 0.01 to 1 part by weight, specifically 0.05 to 0.1 part by weight, based on 100 parts by weight of the cosmetic composition, in consideration of the overall efficacy and manufacturing efficiency of the cosmetic composition.
- the cosmetic composition according to the present invention may further include one or more selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract in order to enhance its function.
- the white rice flower extract may serve to provide a skin elasticity improvement function, the chrysanthemum tree fruit extract a skin soothing function, and the Cellulata cherry tree flower extract an antioxidant function to the cosmetic composition, respectively.
- the content of the white rice flower extract may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight, based on 100 parts by weight of the cosmetic composition, and the The content may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight, and the content of the Cellulata cherry blossom extract may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight.
- the cosmetic composition according to the present invention may further include purified water, antioxidants, stabilizers, pigments, functional additives, or fragrances commonly used in the field of cosmetic compositions.
- the cosmetic composition according to the present invention can be prepared in a conventional formulation. Specifically, it may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, emulsion foundation, wax foundation, or spray.
- the present invention provides a food composition capable of exhibiting effects such as lipolysis and cellulite improvement by including the above-mentioned adipocyte differentiation inhibitor.
- the food composition according to the present invention contains an adipocyte differentiation inhibitor.
- the adipocyte differentiation inhibitor contained in the food composition according to the present invention serves to impart functions such as lipogenesis control, lipolysis, and cellulite improvement to the food composition.
- the description of the adipocyte differentiation inhibitor is the same as described above, and thus will be omitted.
- the content of the adipocyte differentiation inhibitor may be 0.05 to 5 parts by weight, specifically 0.1 to 2 parts by weight, based on 100 parts by weight of the food composition, in consideration of the overall efficacy and manufacturing efficiency of the food composition.
- the food composition according to the present invention may further include one or more selected from the group consisting of white rice flower extract, sycamore tree fruit extract, and cerulata cherry tree flower extract in order to enhance its function.
- the content of the white rice flower extract based on 100 parts by weight of the food composition may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight, and the The content may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight, and the content of the Cellulata cherry blossom extract may be 0.1 to 1 parts by weight, specifically 0.2 to 0.5 parts by weight.
- the food composition according to the present invention further includes flavoring agents, natural carbohydrates, various nutrients, minerals (electrolytes), flavoring agents, coloring agents, organic acids, thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols or carbonating agents, etc. can do.
- glucose, fructose, maltose, sucrose, dextrin, cyclodextrin, xylitol, sorbitol, erythritol, and the like may be used.
- thaumatin As the flavoring agent, thaumatin, rebaudioside A, glycyrrhizin, saccharin and aspartame may be used.
- the food composition according to the present invention can be prepared in a conventional formulation. Specifically, it may be formulated into capsules, tablets, powders, liquids, pills, pastes, syrups, gels, jellies, and the like.
- a golden extract was prepared through the following process using dried golden roots. Specifically, the dried golden root and distilled water were mixed in a weight ratio of 1:10, followed by extraction in a pneumatic extractor 1K pressure and 80 °C conditions for 4 hours to obtain an extract. After the obtained extract was filtered through a 400 mesh polyethylene (PE) sieve, it was mixed with 100% ethanol in a weight ratio of 2.5:7.5 to obtain a golden extract.
- PE polyethylene
- each sample was treated with 3T3-L1 mouse preadipocytes by concentration, and then adipogenesis was measured, and the results are shown in FIG. 1 shown in At this time, the measurement conditions and process were as follows.
- Mouse embryonic fibroblast 3T3-L1 was purchased from ATCC (American Type Culture Collection). Purchased 3T3-L1 was cultured in DEEM (Hyclone) containing 10% fetal bovine serum (FBS, Gibco), 100 U/mL penicillin, and 100 ⁇ g/mL streptomycin.
- DEEM Hyclone
- FBS fetal bovine serum
- streptomycin 100 U/mL penicillin
- streptomycin 100 ⁇ g/mL streptomycin.
- 10 ⁇ g/ml insulin, 0.5 mM 3-isobutyl-1-methylxanthine, and 1 ⁇ M dexamethasone were treated with cultured cells for 2 days, while golden extract was treated with each concentration. After 2 days, 10 ug/ml insulin and a new medium to which golden extract was added were exchanged for culture, and a new medium was exchanged every 2 days. All cultures were performed in a humidified incubator of 5% CO 2 at 37 °C.
- the degree of adipocyte differentiation of 3T3-L1 was analyzed by staining fat with Oil-red-O (Sigma Aldrich) and observing it under an optical microscope, and the amount of fat produced was analyzed by extracting Oil-red-O.
- the differentiated 3T3-L1 cells were fixed with 4% formaldehyde (Sigma Aldrich) for 20 minutes, and then stained with 0.2% Oil-red-O solution for 1 hour. Thereafter, cells were observed under a light microscope (Nikon, Ts2R model) at 200 times magnification. Oil-red-O stained with cells was extracted by treatment with 100% 2-propanol (Sigma Aldrich) for 30 minutes, and then absorbance was measured at 510 nm using a spectrometer (BioTeK).
- Artichoke leaf extract was prepared through the following process using artichoke leaves. Specifically, dried artichoke leaves and 100% ethanol were mixed in a weight ratio of 1:10, followed by extraction at room temperature for 24 hours to obtain an extract. The resulting extract was concentrated by heating to 60 °C, filtered through a 400 mesh polyethylene (PE) sieve, and dried with hot air, and 1 g of the dried extract was mixed with 10 ml of 100% ethanol. Then, it was diluted 20 times with 75% ethanol to obtain an artichoke leaf extract.
- PE polyethylene
- adipogenesis was measured after treatment with the artichoke leaf extract at different concentrations in mouse preadipocytes, and the results are shown in FIG. 2 . At this time, the measurement conditions and procedures were applied in the same manner as in Experimental Example 1.
- An adipocyte differentiation inhibitor in which 25 parts by weight of the golden extract of Preparation Example 1 and 75 parts by weight of purified water were mixed was applied.
- An adipocyte differentiation inhibitor in which 25 parts by weight of the golden extract of Preparation Example 1, 25 parts by weight of the artichoke leaf extract of Preparation Example 2, and 50 parts by weight of purified water were mixed was applied.
- An adipocyte differentiation inhibitor mixed with 25 parts by weight of the golden extract of Preparation Example 1, 25 parts by weight of the artichoke leaf extract of Preparation Example 2, 2 parts by weight of caffeine, and 48 parts by weight of purified water was applied.
- An adipocyte differentiation inhibitor mixed with 25 parts by weight of the golden extract of Preparation Example 1, 25 parts by weight of the artichoke leaf extract of Preparation Example 2, 2 parts by weight of caffeine, 5 parts by weight of tetrapeptide (VHVV), and 43 parts by weight of purified water was applied.
- mice preadipocytes, 3T3-L1 cells, were tested in Examples 1, 2, 3, 4, Comparative Example 1 and Comparative Example 2 Adipocyte differentiation was induced after each of the samples was treated, and the results are shown in FIG. 3 . At this time, the measurement conditions and procedures were applied in the same manner as in Experimental Example 1.
- 3T3-L1 cells which are mouse precursor cells, were treated with the samples of Example 3 and Comparative Example 1 by concentration, respectively, and then adipocyte differentiation was induced. The results are shown in FIG. 4 . At this time, the measurement conditions and procedures were applied in the same manner as in Experimental Example 1.
- Example 3 when 3T3-L1 cells were treated with Example 3, an adipocyte differentiation inhibitor according to the present invention, it was confirmed that the adipogenesis was the lowest at a concentration of 0.2% at 11.2%.
- Example 3 and Comparative Example 1 were treated in differentiated 3T3-L1 adipocytes, respectively, and then cultured for 48 hours. Then, it was observed with an optical microscope, and the amount of fat was measured by Oil-red-O staining described in Experimental Example 1, and the results are shown in FIG. 5 .
- Example 3 which is an adipocyte differentiation inhibitor according to the present invention, the amount of fat decreased by 48.2%, and thus it was confirmed that the lipolysis efficacy was excellent.
- Example 3 and Comparative Example 1 were respectively treated in 3T3-L1 cells, which are mouse preadipocytes.
- 3T3-L1 cells which are mouse preadipocytes.
- adipocyte protein 2 aP2
- PPAR- ⁇ peroxisome proliferator-activated receptor gamma
- ADIPOQ adiponectin
- Example 3 and Comparative Example 1 After culturing 3T3-L1 cells, which are preadipocytes, in a 6 well plate, differentiation into adipocytes was induced. At this time, each sample of Example 3 and Comparative Example 1 was treated for 48 hours by concentration, washed with phosphate buffered saline (Hyclone, PBS), 1 mL of TRIzol Reagent (Invitrogen) was added to each cell, and then a 1.5 ml tube moved to After adding and mixing 200 ⁇ L of Chloroform (Sigma aldrich), the mixture was reacted at room temperature for 3 minutes, and then centrifuged at 13,000 rpm at 4 °C for 10 minutes to separate the RNA layer.
- phosphate buffered saline Hyclone, PBS
- TRIzol Reagent Invitrogen
- RNA was taken and the same amount of isopropanol (Sigma Aldrich) was added, mixed for 10 minutes, and then centrifuged at 4 °C at 13,000 rpm for 10 minutes. The centrifuged RNA was washed twice with ethanol, dried, dissolved in nuclease-free purified water, and the concentration was measured. The extracted RNA was cDNA synthesized using TOPscript TM One-step RT PCR kit (Enzynomics).
- Example 3 which is an adipocyte differentiation inhibitor according to the present invention
- the mRNA expression levels of aP2, PPAR-r, and ADIPOQ decreased by 15.6%, 3.6%, and 12.7%, respectively, at a concentration of 0.2%, thereby inhibiting adipocyte differentiation. This excellent thing could be confirmed.
- a cosmetic composition was prepared using the adipocyte differentiation inhibitor of Example 4. Specifically, 2.0 parts by weight of 1,2-hexanediol, 3.0 parts by weight of panthenol, 3.0 parts by weight of 1,3-butylene glycol, 2.0 parts by weight of glycerin purified water 72 It was put in parts by weight and stirred at 1,000 rpm for 10 minutes to prepare an aqueous solution.
- an oily lysate 6.0 parts by weight of cetylethylhexanoade (oil), 6.0 parts by weight of caprylic/capric triglyceride, 2.0 parts by weight of ethylhexylolivate, 1.0 parts by weight of cetearylorivate 80 Dissolved by heating at °C, the prepared aqueous phase lysate was added and stirred at 1,000 rpm to prepare an oil phase lysate. Then, 2.4 parts by weight of the adipocyte differentiation inhibitor of Example 4, 1.0 parts by weight of white rice flower extract, and 0.05 parts by weight of sponge spicule were additionally added and stirred at 2,000 rpm at 60° C. for 5 minutes to obtain a creamy cosmetic composition. prepared.
- a cosmetic composition of a cream formulation was prepared through the same procedure as in Preparation Example 1, except that 0.5 parts by weight of the sycamore tree fruit extract and 0.5 parts by weight of the cerulata cherry blossom extract were further added. At this time, the composition was adjusted by reducing the content of purified water as much as the contents of the added Prunus asiatica extract and Cerulata cherry tree flower extract.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (9)
- 황금추출물; 및 아티초크잎추출물을 포함하는 지방세포 분화 억제제.
- 제1항에 있어서,상기 황금추출물은 바이칼레인(Baicalein), 바이칼린(Baicalin), 디하이드로바이칼레인(Dihydrobaicalein), 오록실린 A(Oroxylin A), 디하이드로오록실린 A(Dihydrooroxylin A), 오고닌(Wogonin) 및 노르오고닌(Norwogonin)으로 이루어진 군에서 선택되는 1종 이상을 포함하는 것인 지방세포 분화 억제제.
- 제1항에 있어서,상기 황금추출물과 상기 아티초크잎추출물의 혼합비율이 1:1 내지 5:1의 중량비인 것인 지방세포 분화 억제제.
- 제1항에 있어서,카페인, 펩타이드 및 은행나무잎추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함하는 것인 지방세포 분화 억제제.
- 제4항에 있어서,상기 펩타이드는 Valine-Histidine-Valine-Valine(VHVV), Isoleucine-Leucine-Leucine(ILL) 및 Leucine-Leucine-Leucine(LLL)로 표시되는 펩타이드로 이루어진 군에서 선택되는 1종 이상인 것인 지방세포 분화 억제제.
- 제1항 내지 제5항 중 어느 한 항에 따른 지방세포 분화 억제제; 및스피큘을 포함하는 화장료 조성물.
- 제6항에 있어서,상기 스피큘이 가수분해 단백질 또는 친수성 물질로 코팅된 것인 화장료 조성물.
- 제6항에 있어서,백미꽃추출물, 회화나무열매추출물 및 세룰라타벚나무꽃추출물로 이루어진 군에서 선택되는 1종 이상을 더 포함하는 것인 화장료 조성물.
- 제1항 내지 제5항 중 어느 한 항에 따른 지방세포 분화 억제제를 포함하는 식품 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200068749 | 2020-06-08 | ||
KR10-2020-0068749 | 2020-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021251603A1 true WO2021251603A1 (ko) | 2021-12-16 |
Family
ID=78845694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/004242 WO2021251603A1 (ko) | 2020-06-08 | 2021-04-06 | 지방세포 분화 억제제 및 이를 포함하는 조성물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20210152372A (ko) |
WO (1) | WO2021251603A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130095798A (ko) * | 2011-01-21 | 2013-08-28 | 라이온 가부시키가이샤 | 지방 분해 촉진 조성물 |
KR20130134976A (ko) * | 2012-05-31 | 2013-12-10 | 주식회사 코스메카코리아 | 백미 추출물을 함유하는 피부 미백 화장료 조성물 |
KR101515865B1 (ko) * | 2015-03-02 | 2015-05-04 | 박성율 | 미백 효능을 가진 적하수오와 흑삼 발효 추출물을 이용한 조성물로 피부를 6단계적으로 관리 개선하는 방법 |
KR101757841B1 (ko) * | 2014-11-12 | 2017-07-14 | 한국생명공학연구원 | 바이칼린-아연착염을 포함하는 비만억제용 조성물 |
KR102074214B1 (ko) * | 2019-09-06 | 2020-02-06 | 주식회사 에이치앤비나인 | 경피 흡수 촉진용 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101865914B1 (ko) | 2016-02-25 | 2018-06-12 | 오명진 | 지방분해 및 셀룰라이트 개선 성분을 함유하는 다이어트 주사용 조성물 |
-
2021
- 2021-03-19 KR KR1020210035662A patent/KR20210152372A/ko not_active Application Discontinuation
- 2021-04-06 WO PCT/KR2021/004242 patent/WO2021251603A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130095798A (ko) * | 2011-01-21 | 2013-08-28 | 라이온 가부시키가이샤 | 지방 분해 촉진 조성물 |
KR20130134976A (ko) * | 2012-05-31 | 2013-12-10 | 주식회사 코스메카코리아 | 백미 추출물을 함유하는 피부 미백 화장료 조성물 |
KR101757841B1 (ko) * | 2014-11-12 | 2017-07-14 | 한국생명공학연구원 | 바이칼린-아연착염을 포함하는 비만억제용 조성물 |
KR101515865B1 (ko) * | 2015-03-02 | 2015-05-04 | 박성율 | 미백 효능을 가진 적하수오와 흑삼 발효 추출물을 이용한 조성물로 피부를 6단계적으로 관리 개선하는 방법 |
KR102074214B1 (ko) * | 2019-09-06 | 2020-02-06 | 주식회사 에이치앤비나인 | 경피 흡수 촉진용 구조체, 이의 제조방법 및 이를 포함하는 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20210152372A (ko) | 2021-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017052267A1 (ko) | 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물 | |
JP5628797B2 (ja) | 人参の花または人参の種子抽出物を含有する皮膚外用剤組成物 | |
WO2017123022A1 (ko) | 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀 | |
CN104644461B (zh) | 具有促进胶原蛋白合成活性的化合物在抗衰老化妆品中的应用 | |
KR100853761B1 (ko) | 노각나무 추출물 및 그 용도 | |
EP1082098A1 (fr) | Procede de traitement cosmetique pour lutter contre les effets du vieillissement cutane | |
WO2019066538A1 (ko) | 식물 유래 세포 외 소포체를 포함하는 조성물 | |
WO2013089449A1 (ko) | 홍삼 먹인 달팽이 점액을 함유하는 화장료 조성물 및 그 제조방법 | |
WO2018174453A1 (ko) | 엉겅퀴 추출물을 유효성분으로 포함하는 멜라닌 생성 촉진용 조성물 | |
TWI747280B (zh) | 余甘子萃取發酵物及其製備與應用 | |
WO2018194360A1 (ko) | 피부 개선용 조성물 | |
WO2020218888A1 (ko) | 신규한 락토바실러스 람노서스 lm1011을 유효성분으로 포함하는, 피부 미백용 화장료 조성물 | |
WO2017200288A1 (ko) | 천연 한방 추출물을 유효성분으로 포함하는 미백, 피부 노화 방지 또는 피부 주름 개선용 조성물 | |
WO2016021934A1 (ko) | 아스파라거스 추출물을 함유하는 팽창선조 예방 또는 개선용 조성물 | |
WO2012173382A2 (ko) | 탄시논ⅱa를 유효성분으로 함유하는 피부 외용제 조성물 | |
WO2016056781A1 (ko) | 알파인 웜우드 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
WO2021251603A1 (ko) | 지방세포 분화 억제제 및 이를 포함하는 조성물 | |
WO2016056780A1 (ko) | 알피나 골무꽃 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
WO2010058986A2 (en) | Cosmetic composition containing extracts of adenophora triphylla var. japonica hara, angelica tenuissima and medicinal herbs | |
WO2023128426A1 (ko) | 솔잎 발효 추출물을 포함하는 화장료 조성물 | |
WO2021215882A1 (ko) | 동백나무 과피 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2021033994A1 (ko) | 단삼 또는 작약 추출물을 유효성분으로 함유하는 지질대사질환 예방 또는 치료용 조성물 | |
WO2018194359A1 (ko) | 피부 개선용 조성물 | |
KR101273027B1 (ko) | 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물 | |
WO2016171482A1 (ko) | 봉독 추출물을 포함하는 화장료 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21821340 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21821340 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21821340 Country of ref document: EP Kind code of ref document: A1 |